Company intelligence / Profile preview
Oqory, Inc.
San Diego, California, United Statesoqory.com ↗
- Ownership
- Private
- Development stage
- Phase 3
01
Overview
OQY-3258 has shown an 83% overall response rate and 100% disease control rate in first-line triple-negative breast cancer (n=30). No cases of interstitial lung disease or Grade 3 and above stomatitis have been reported, suggesting a favorable safety profile compared to other TROP2 ADCs.
- Therapeutic areas
- Oncology
- Modalities
- Antibody-drug conjugates (ADCs)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Proposed merger with Vincerx Pharma, Inc.
Beyond the preview
Go deeper on Oqory, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Oqory, Inc..